Organon

Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer

Retrieved on: 
木曜日, 11月 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pfizer, Integra, Chemistry, MTX, Kyowa Kirin, University College Utrecht, Patient, Multimedia, Isoti, FDA, Alliance Manchester Business School, IPO, MBA, University, Partnership, Integra LifeSciences, Fast Track, Organon, Management

Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).

Key Points: 
  • Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).
  • View the full release here: https://www.businesswire.com/news/home/20231115733368/en/
    Erik van den Berg, CEO of Memo Therapeutics AG (Photo: Business Wire)
    Mr. van den Berg joins MTx with over 25 years’ industry experience and proven track record in leading and growing companies.
  • Previously, Mr. van den Berg also held business development roles at Organon and IsoTis (sold to Integra Lifesciences).
  • Mr. van den Berg holds a master’s degree in chemistry from the University of Utrecht and an MBA from Manchester Business School.

700 LATINO LEADERS GATHER AT THE UNITED NATIONS TO AGREE ON THEIR COMMON AGENDA FOR A CRITICAL YEAR TO COME

Retrieved on: 
水曜日, 12月 6, 2023
P&G, City National Bank, IBM, JPMorgan Chase, Advertising, Eli Lilly, Publicis, Hispanic, World Games, Sustainability, Bank, Synchrony, Heart, Telemundo, Anheuser-Busch, Summit, Yum! Brands, Content, Ashoka, GLAAD, Eye, Salesforce, Teach For America, Paramount, Revolution, Directory, Beam Suntory, AARP, For America, Workplace, SVP, Dallas Regional Chamber, Toronto-Dominion Bank, Safe space, USTA, Lyft, Ally, Gold medal, BMS, Walmart, Wells Fargo, Perindopril, NRG, Nightclub, Management, Bottled water, Latino, PepsiCo, Nationwide, Northwell Health, Aeroméxico, U.S. Bancorp, Organon, Coca-Cola

NEW YORK, Dec. 6, 2023 /PRNewswire/ -- The We Are All Human Foundation  kicked off today the sixth Hispanic Leadership Summit, bringing together leaders from the public, private and non-profit sectors to create an annual agenda designed to advance the prosperity, power and progress of Latinos.

Key Points: 
  • The programming includes the implementation of playbooks, resources and toolkits to equip corporate America and other players to create robust Latino strategies.
  • "The Hispanic Leadership Summit has become an important part of how the We Are All Human Foundation works to unite the Latino community in order to advance the Latino path to progress.
  • The critical issues for our community remain changing perceptions and representation.
  • For two days, some of America's best corporations meet with community and non-profit organizations to share learnings and build consensus around priorities and programs.

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
木曜日, 11月 9, 2023
Cream, Female, FDA, Bacterial vaginosis, Research, Human development, Trial of the century, Cooperative research and development agreement, Vaginal discharge, Food, Hot, Organon, Human services, Eunice Kennedy Shriver National Institute of Child Health and Human Development, G&A, Progesterone, Phase 3, Quarter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Call, Development, NICHD, Webcast, Clinical trial, ID, Tamoxifen, FSAD, Bacteria, Hormone, NIH, Woman, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Patient, Bangladesh Technical Education Board, Pharmaceutical industry, Birth control, Bayer, Conference

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update.

Key Points: 
  • ET
    SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update.
  • XACIATO™ provides a new therapeutic option for the millions of women suffering from bacterial vaginosis in the U.S.
  • Financial Highlights for the Quarter ended September 30, 2023
    Cash and cash equivalents: $13.8 million at September 30, 2023.
  • Daré will host a conference call and live webcast today, November 9, 2023, at 4:30 p.m. Eastern Time to review financial results for the quarter ended September 30, 2023 and to provide a company update.

Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®

Retrieved on: 
火曜日, 11月 7, 2023
FDA, Psoriasis, NYSE, Food, Organon, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, OGN, Pharmacy, Head, Patient, Regulatory affairs, Pharmaceutical industry, Adalimumab

The sBLA was submitted to the FDA by Samsung Bioepis in August 2023.

Key Points: 
  • The sBLA was submitted to the FDA by Samsung Bioepis in August 2023.
  • We remain committed to helping more patients access biosimilar alternatives,” said Jon Martin, Head, US Biosimilars at Organon.
  • HADLIMA (adalimumab-bwwd) was first approved by the FDA in July 2019 as a low-concentration (40 mg/0.8 mL) formulation of prefilled syringe and prefilled autoinjector.
  • HADLIMA was introduced into the US commercial market on July 1, 2023 and is marketed by Organon.

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

Retrieved on: 
火曜日, 11月 7, 2023
FDA, Janssen, Organon, G&A, Inflammation, Place of birth, NDA, License, End-user license agreement, Glioma, Video game, Cryptocurrency, Pharmaceutical industry

EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its third quarter 2023 financial results and highlighted recent portfolio activities expected to drive long-term shareholder value.

Key Points: 
  • XOMA recorded total revenues of $0.8 million for the third quarter of 2023 and $0.5 million for the third quarter of 2022.
  • General and administrative (“G&A”) expenses were $6.4 million for the third quarter of 2023, compared to $4.8 million for the third quarter of 2022.
  • In the third quarter of 2023, G&A expenses included $2.7 million in non-cash stock-based compensation expense, compared with $0.8 million in the third quarter of 2022.
  • Other income, net was $0.3 million for the third quarter of 2023 and $0.2 million in the corresponding quarter of 2022.

Syniti Announces Strong Third Quarter 2023 Results Propelled by Data First Strategy

Retrieved on: 
火曜日, 11月 7, 2023
Cloud, Knowledge, Linda, Carbon, Female, Woman, Lion, Carbon Disclosure Project, ARR, SKP, Organon, Synthetic media, Merck, Generative, ACV, APJ, Data management, Stevie Awards, Growth, Marketing, SAP, HR, SAP Solution Manager, OpenAI, CFO, Success, Foodservice, Music, Cryptocurrency, Management, Information technology

BOSTON, Nov. 7, 2023 /PRNewswire/ -- Syniti, a global leader in enterprise data management, today announced key financial and company highlights for the third quarter of 2023. New and repeat customers are responding to Syniti's Data First strategy which advocates the importance of starting data alongside or even before global design during digital and business transformation efforts. As businesses realize that "good enough" shouldn't apply to the quality of their data, they continue to ask Syniti and its team of data experts to take a principal role in leading the crucial stages of their transformation projects.

Key Points: 
  • New and repeat customers are responding to Syniti's Data First strategy which advocates the importance of starting data alongside or even before global design during digital and business transformation efforts.
  • Syniti added 10 significant new logos in the quarter, expanding its client base globally and deepening its expertise with Global2000 oil & gas and aerospace & defense enterprises.
  • Syniti closed its highest quarter ever in license volume with SAP, underpinning the importance of data in driving digital transformation with SAP S/4HANA Cloud.
  • Syniti has leveraged its own Rapid Data Governance solution framework to create this series of prepackaged, custom objects to accelerate data governance activities across various SAP Master Data Governance domains.

Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors

Retrieved on: 
月曜日, 11月 6, 2023
Actinium, Therapy, Ophthalmology, Organon, AMD, Merck, Acquisition, Schering-Plough, Research, Drug development, Bayer, University, Schizophrenia, Pembrolizumab, Knowledge management, AbbVie, Depression, University of Wales, Newport, Patient, Mirtazapine, Pharmaceutical industry, Volastra, Bimatoprost, Adverum Biotechnologies, Allergan

"We are excited to welcome David to Adverum’s Board of Directors.

Key Points: 
  • "We are excited to welcome David to Adverum’s Board of Directors.
  • He brings an exceptional breadth of experience and a track record of success in pharmaceutical R&D and has launched multiple transformative products throughout his career, notably in ophthalmology," stated Patrick Machado, J.D., board chair of Adverum Biotechnologies.
  • “On behalf of the management team at Adverum, I’d like to extend a warm welcome to David,” added Laurent Fischer, M.D., president and chief executive officer of Adverum.
  • from the University of Manchester and his Ph.D. from the University of Wales.

Organon Returns Ebopiprant to XOMA

Retrieved on: 
金曜日, 10月 27, 2023
SIX Swiss Exchange, Sale, Partnership, Health, Pharmaceutical industry, Organon

53 LR of the SIX Swiss Exchange

Key Points: 
  • 53 LR of the SIX Swiss Exchange
    Geneva, Switzerland – October 27, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that XOMA will be receiving full worldwide rights on ebopiprant, an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist, following the termination of the license agreement with Organon.
  • After positive Phase 2a results in November 2020, ObsEva granted a license to Organon in July 2021 for the global development, manufacturing, and commercial rights to ebopiprant.
  • In November 2022, ObsEva sold and assigned to XOMA all its rights to ebopiprant, including the Company’s license agreement with Organon, and the intellectual property estate.
  • In addition to the $15 million received in upfront proceeds from the sale, ObsEva was eligible to receive certain milestones under the license agreement with Organon for ebopiprant.

Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors

Retrieved on: 
月曜日, 11月 6, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, EVP, Bayer, Pembrolizumab, Chairperson, PD-1, Merck, Schering-Plough, Research, University, Cancer, Therapy, University of Wales, Newport, Patient, Doctor of Philosophy, Pharmaceutical industry, Volastra, Organon, Pharmacology

Volastra Therapeutics , a clinical-stage cancer biotechnology company, today announced the appointment of David Nicholson, Ph.D., as an independent member of its Board of Directors.

Key Points: 
  • Volastra Therapeutics , a clinical-stage cancer biotechnology company, today announced the appointment of David Nicholson, Ph.D., as an independent member of its Board of Directors.
  • Nicholson joins our board as the company is moving expeditiously through the clinic with two novel, differentiated oral KIF18A inhibitors, as well as a pipeline of synthetic lethal and immune-activating assets,” said Sandi Peterson, Chair of the Board.
  • Dr. Nicholson most recently served as EVP and Global Head of Research and Development at Allergan Pharmaceuticals.
  • Dr. Nicholson currently serves as the Chair of the Board of Exscientia, a world-leading artificial intelligence company focused on immunology, immuno-oncology and oncology.

Organon Reports Results for the Third Quarter Ended September 30, 2023

Retrieved on: 
木曜日, 11月 2, 2023
Biotechnology, Women, Consumer, Health, Pharmaceutical, Organon, EBITDA, IPR, GAAP, Adalimumab, Acquisition, Bank, Adjustment, Etonogestrel

Net income for the third quarter of 2023 was $58 million, or $0.23 per diluted share, compared with $227 million, or $0.89 per diluted share, in the third quarter of 2022.

Key Points: 
  • Net income for the third quarter of 2023 was $58 million, or $0.23 per diluted share, compared with $227 million, or $0.89 per diluted share, in the third quarter of 2022.
  • The dividend is payable on December 14, 2023, to stockholders of record at the close of business on November 13, 2023.
  • These items are uncertain, depend on various factors, and could be material to Organon’s results computed in accordance with GAAP.
  • The company is updating its full year 2023 guidance ranges previously provided on August 8, 2023.